Therapeutic Area
Nephrology and cardiorenal studies
Sponsor-facing capability for CKD, diabetic kidney disease, cardiorenal syndrome, IgA nephropathy, and dialysis-access protocols at Amavita Research in Miami.
Kidney and cardiovascular disease travel together, and modern trial pipelines increasingly reflect that. Amavita Research's cardiorenal capability builds on the cardiovascular infrastructure already running our trials: a board-certified nephrologist (FASN) investigator works alongside our cardiovascular investigators, so CKD, diabetic kidney disease, cardiorenal, IgA nephropathy, and dialysis-access protocols can use the same site operations, coordinators, regulatory, and quality systems already in place. For cardiorenal protocols in particular, sponsors get cardiology and nephrology oversight under one site.
Protocol areas covered
- Chronic kidney disease (CKD)
- Diabetic kidney disease
- Cardiorenal syndrome
- IgA nephropathy
- Dialysis access
Why Amavita Research for nephrology and cardiorenal studies
- A board-certified nephrologist (FASN) investigator works alongside our cardiovascular investigators, so cardiorenal protocols benefit from cardiology and nephrology oversight under one site.
- The same site operations, coordinators, regulatory, and quality systems already running our cardiovascular trials carry over to nephrology and cardiorenal protocols.
- 8 monitored observation beds with continuous ECG telemetry inside the affiliated cardiovascular ambulatory surgery center (Advanced Cardiovascular of Miami, Kendall), supporting same-day scope.
- On-site IV infusion capability and same-day central-lab handling per ICH-GCP E6(R3).
- Bilingual screening and coordination in English, Spanish, Haitian Creole, and Portuguese for Miami's multilingual patient population.
Current status
This page describes site capability for sponsors evaluating Amavita Research for a nephrology or cardiorenal protocol. We are not currently enrolling nephrology trials. Feasibility questions are answered within one business day.